You are currently viewing a new version of our website. To view the old version click .

Antibodies, Volume 8, Issue 4

December 2019 - 10 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (10)

  • Review
  • Open Access
196 Citations
38,975 Views
30 Pages

IgA: Structure, Function, and Developability

  • Patrícia de Sousa-Pereira and
  • Jenny M. Woof

5 December 2019

Immunoglobulin A (IgA) plays a key role in defending mucosal surfaces against attack by infectious microorganisms. Such sites present a major site of susceptibility due to their vast surface area and their constant exposure to ingested and inhaled ma...

  • Review
  • Open Access
78 Citations
19,958 Views
48 Pages

4 December 2019

Monoclonal antibodies (mAbs) are currently the largest and most dominant class of therapeutic proteins. Inter-individual variability has been observed for several mAbs; however, an understanding of the underlying mechanisms and factors contributing t...

  • Review
  • Open Access
453 Citations
98,952 Views
80 Pages

Antibody Structure and Function: The Basis for Engineering Therapeutics

  • Mark L. Chiu,
  • Dennis R. Goulet,
  • Alexey Teplyakov and
  • Gary L. Gilliland

3 December 2019

Antibodies and antibody-derived macromolecules have established themselves as the mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure–function relationships of antibodies provides a platform for protein e...

  • Article
  • Open Access
25 Citations
10,711 Views
20 Pages

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

  • Efrat T. Harel,
  • Penelope M. Drake,
  • Robyn M. Barfield,
  • Irene Lui,
  • Shauna Farr-Jones,
  • Laura Van’t Veer,
  • Zev J. Gartner,
  • Evan M. Green,
  • André Luiz Lourenço and
  • Yifan Cheng
  • + 3 authors

5 November 2019

A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocyto...

  • Article
  • Open Access
10 Citations
8,893 Views
11 Pages

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV

  • Lili Wang,
  • Jiyan Xu,
  • Yu Kong,
  • Ruiying Liang,
  • Wei Li,
  • Jinyao Li,
  • Jun Lu,
  • Dimiter S. Dimitrov,
  • Fei Yu and
  • Yanling Wu
  • + 1 author

4 November 2019

In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our kn...

  • Review
  • Open Access
30 Citations
17,599 Views
13 Pages

Immunoglobulin for Treating Bacterial Infections: One More Mechanism of Action

  • Teiji Sawa,
  • Mao Kinoshita,
  • Keita Inoue,
  • Junya Ohara and
  • Kiyoshi Moriyama

3 November 2019

The mechanisms underlying the effects of immunoglobulins on bacterial infections are thought to involve bacterial cell lysis via complement activation, phagocytosis via bacterial opsonization, toxin neutralization, and antibody-dependent cell-mediate...

  • Review
  • Open Access
43 Citations
9,860 Views
54 Pages

Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors

  • Nicholas Gravbrot,
  • Kacy Gilbert-Gard,
  • Paras Mehta,
  • Yarah Ghotmi,
  • Madhulika Banerjee,
  • Christopher Mazis and
  • Srinath Sundararajan

21 October 2019

Recently, modulation of immune checkpoints has risen to prominence as a means to treat a number of solid malignancies, given the durable response seen in many patients and improved side effect profile compared to conventional chemotherapeutic agents....

  • Communication
  • Open Access
11 Citations
6,363 Views
12 Pages

NR4A Expression by Human Marginal Zone B-Cells

  • Kim Doyon-Laliberté,
  • Josiane Chagnon-Choquet,
  • Michelle Byrns,
  • Matheus Aranguren,
  • Meriam Memmi,
  • Pavel Chrobak,
  • John Stagg,
  • Johanne Poudrier and
  • Michel Roger

11 October 2019

We have previously characterized a human blood CD19+CD1c+IgM+CD27+CD21loCD10+ innate-like B-cell population, which presents features shared by both transitional immature and marginal zone (MZ) B-cells, named herein “precursor-like” MZ B-c...

  • Article
  • Open Access
19 Citations
8,218 Views
19 Pages

The Impact of Immunoglobulin G1 Fc Sialylation on Backbone Amide H/D Exchange

  • Felix Kuhne,
  • Lea Bonnington,
  • Sebastian Malik,
  • Marco Thomann,
  • Cecile Avenal,
  • Florian Cymer,
  • Harald Wegele,
  • Dietmar Reusch,
  • Michael Mormann and
  • Patrick Bulau

1 October 2019

The usefulness of higher-order structural information provided by hydrogen/deuterium exchange-mass spectrometry (H/DX-MS) for the structural impact analyses of chemical and post-translational antibody modifications has been demonstrated in various st...

  • Article
  • Open Access
8 Citations
12,253 Views
19 Pages

Distinguishing Between Monomeric scFv and Diabody in Solution Using Light and Small Angle X-ray Scattering

  • Frank Lüdel,
  • Sandra Bufe,
  • Willem M. Bleymüller,
  • Hugo de Jonge,
  • Luisa Iamele,
  • Hartmut H. Niemann and
  • Thomas Hellweg

23 September 2019

Depending on the linker length between the V H and the V L domain, single-chain Fv (scFv) antibody fragments form monomers, dimers (diabodies) or higher oligomers. We aimed at generating a diabody of the anti-MET antibody 3H3 to use i...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Antibodies - ISSN 2073-4468